Comparison of three pharmacovigilance algorithms in the ICU setting: A retrospective and prospective evaluation of ADRs

Drug Safety

Volumn 35, Issue 8, 2012, Pages 645-653

  Kane Gill, Sandra L ^a,b,c   Forsberg, Elizabeth A ^d   Verrico, Margaret M ^a,b   Handler, Steven M ^c,e,f  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d St Margaret Memorial Hospital   (United States)

^e Geriatric Pharmaceutical Outcomes and Geroinformatics Research and Training Program   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Adverse drug reactions; Algorithm; Intensive care units; Pharmacovigilance

Indexed keywords

ADVERSE DRUG REACTION; ALGORITHM; ARTICLE; CONTROLLED STUDY; DRUG SURVEILLANCE PROGRAM; HUMAN; INTENSIVE CARE UNIT; INTERMETHOD COMPARISON; JONES ALGORITHM; KRAMER ALGORITHM; NARANJO CRITERIA; PRIORITY JOURNAL; SCORING SYSTEM;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ALGORITHMS; DRUG MONITORING; DRUG TOXICITY; HUMANS; INTENSIVE CARE UNITS; PENNSYLVANIA; PHARMACEUTICAL PREPARATIONS; PHARMACOVIGILANCE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 84863853546     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11599730-000000000-00000     Document Type: Article

References (48)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200-5 (Pubitemid 28193431)
2. Kane-Gill SL, Weber RJ. Principles and practices of medication errors in the ICU. Crit Care Clin 2006; 22: 273-90
3. Cullen DJ, Sweitzer BJ, Bates DW, et al. Preventable adverse drug events in hospitalized patients: a comparative study of intensive care units and general care units. Crit Care Med 1997; 25 (8): 1289-97 (Pubitemid 27347291)
4. Rothschild JM, Landrigan CP, Cronin JW, et al. The Critical Care Safety Study: the incidence and nature of adverse events and serious medical errors in intensive care. Crit Care Med 2005; 33 (8): 1694-700 (Pubitemid 41153692)
5. Weingart SN, Toth M, Sandz DZ, et al. Physician's decisions to override computerized drug alerts in primary care. Arch Intern Med 2003; 163: 2625-31 (Pubitemid 37464421)
6. Karch FE, Smith CL, Kerzner B, et al. Adverse drug reactions: a matter of opinion. Clin Pharmacol Ther 1976; 19: 489-92
7. Arimone Y, Begaud B, Miremone-Salame G, et al. Agreement of expert judgment in causality assessment of adverse drug reactions. Eur J Clin Pharmacol 2005; 61: 169-73 (Pubitemid 40768547)
8. Benahmed S, Picot MC, Hillaire-Buys D, et al. Comparison of pharmacovigilance algorithms in drug hypersensitivity reactions. Eur J Clin Pharmacol 2005; 61: 537-41 (Pubitemid 41218825)
9. Kramer MS, Leventhal JM, Huchinson TA, et al. An algorithm for the operational assessment of adverse drug reactions. JAMA 1979; 242: 623-32
10. Jones JK. Definition of events associated with drugs: regulatory perspectives. J Rheumatol 1988; 15: 14-9 (Pubitemid 18261072)
11. Irey NS. Tissue reactions to drugs. Am J Pathol 1976; 82: 613-48
12. Karch FE, Lasanga L. Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther 1997; 21: 247-54
13. Dangomanu J, Evereux JC, Jouglard J. Method for determination of undesirable effects of drugs [in French]. Therapie 1978; 33: 373-81 (Pubitemid 8366026)
14. Begaud B, Evreux JC, Jouglard J, et al. Imputation of the unexpected or toxic effects of drugs: actualization of the method used in France. Therapie 1985; 40: 111-8
15. Blanc S, Leuenberger P, Berger JP, et al. Judgments of trained observers on adverse drug ractions. Clin Pharmacol Ther 1979; 25: 493-8 (Pubitemid 9208905)
16. Emanueli A, Sacchetti G. An algorithm for the classification of untoward events in large scale clinical trials. Agents Actions Suppl 1980; 7: 318-22
17. Evreux JC, Loupi E, Descotes J, et al. Evaluation of the documentation on adverse effects of drugs: proposition 2. Imputability [in French]. Therapie 1982; 37: 657-70 (Pubitemid 13221078)
18. Kitaguchi T, Nojiri T, Suzuki S, et al. Some assessment systems for industry post marketing adverse drug reaction (ADR) information. Iyakuhin Kenkyu 1983; 38: 303-18
19. Lagier G, Vincens M, Castot A. Imputability in drug monitoring: principles of the balanced drug reaction assessment method and principal errors to avoid. Therapie 1983; 38: 303-18 (Pubitemid 13026538)
20. Cornelli U. The phase IV monitoring studies: examples of naproxen Na multi-centre Italian trial. In: Crescioni C, James JM, editors. Postmarketing clinical trials: the phase V studies. Paris: Editions de Sante, 1984: 89-105
21. Stephens MD. Assessment of causality in industrial setting. Special workshop: industrial. Drug Inf J 1984; 18: 307-13
22. Castle WM. Assessment of causality in industrial settings. Drug Inf J 1984; 18: 297-302
23. Turner WM. The Food and Drug Administration algorithm. Special workshop: regulatory. Drug Inf J 1984; 18: 259-66
24. Venulet J, Ciucci A, Berneker GC. Standardised assessment of drug-adverse reaction associations: rationale and experience. Int J Clin Pharmacol Ther Toxicol 1980; 18: 381-8 (Pubitemid 10061773)
25. Loupi E, Ponchon AC, Ventre JJ, et al. Imputability of a teratogenic effect [in French]. Therapie 1986; 41: 207-10
26. Stricker BHC. Diagnosis and causality assessment of druginduced hepatic injury. In: Dukes MNG, editor. Druginduced hepatic injury. Amsterdam: Elsevier, 1985: 1-13
27. Benichou C, Danan G. Causality assessment in the European pharmaceutical industry: presentation of the preliminary results of a new method. Drug Inf J 1992; 26: 589-92
28. Hoskins RE, Mannino S. Causality assessment of adverse drug reactions using decision support and informatics tools. Pharmacoepidemiol Drug Saf 1992; 1: 235-49
29. Danan G, Benichou C. Causality assessment of adverse reactions to drugs: I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323-30 (Pubitemid 23333873)
30. Hsu PH, Stoll RW. Causality assessment of adverse events in clinical trials: II. An algorithm for drug causality assessment. Drug Inf J 1993; 27: 387-94 (Pubitemid 23167350)
31. Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997; 26: 664-9 (Pubitemid 27392358)
32. Koh Y, Shu CL. A new algorithm to identify the causality of adverse drug reactions. Drug Saf 2005; 28: 1159-61 (Pubitemid 41776006)
33. Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007; 41: 674-80 (Pubitemid 46625492)
34. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 329-45
35. Kelly WN. The quality of adverse drug event reports. Ann Pharmacother 2003; 37: 1774-8 (Pubitemid 37466569)
36. Kane-Gill SL, Devlin JW. Adverse drug event reporting in the intensive care unit: a survey of current practices. Ann Pharmacother 2006; 40: 1267-73 (Pubitemid 44204955)
37. Steinman MA, Handler SM, Gurwitz JH, et al. Beyond the prescription: medication monitoring and adverse drug events in older adults. J Am Geriatr Soc 2011; 59 (8): 1513-20
38. Kane-Gill SL, Visweswaran S, Saul MI, et al. Computerized detection of adverse drug reactions in the medical intensive care unit. Int J Med Inform 2011; 80 (8): 570-8
39. Michel DJ, Knodel LC. Comparison of three algorithms used to evaluate adverse drug reactions. Am J Hosp Pharm 1986; 43 (7): 1709-14 (Pubitemid 16059508)
40. Goh CL. An approach to the evaluation and documentation of adverse drug reaction. Sing Med J 1989; 30: 283-5
41. Kane-Gill SL, Bellamy CJ, Verrico MM, et al. Evaluating the positive predictive values of antidote signals to detect potential adverse drug reactions (ADRs) in the medical intensive care unit (ICU). Pharmacoepidemiol Drug Saf 2009; 18: 1185-91
42. Oderda GM, Said Q, Evans RS, et al. Opioid-related adverse drug events in surgical hospitalizations: impact on costs and length of stay. Ann Pharmacother 2007; 41: 400-7 (Pubitemid 46536029)
43. Dormann H, Muth Selbach U, Krebs S, et al. Incidence and costs of adverse reactions during hospitalization. Drug Saf 2000; 22: 161-8
44. Evans RS, Pestotnik SL, Classen DC, et al. Preventing adverse drug events in hospitalized patients. Ann Pharmacother 1994; 28: 523-7 (Pubitemid 24123771)
45. Kilbridge PM, Campbell UC, Cozart HB, et al. Automated surveillance for adverse drug events a community hospital and an academic medical center. J Am Med Inform Assoc 2006; 13: 372-7 (Pubitemid 43947628)
46. Stokes MB, Davis CS, Knoch GC. Categorical data analysis using the SAS system. Cary (NC): SAS Institute Inc., 1995
47. Kane-Gill SL, Kirisci L, Pathak DS. Are the Naranjo criteria reliable and valid for determination of adverse drug reactions in the intensive care unit? Ann Pharmacother 2005; 39 (11): 1823-7 (Pubitemid 41527694)
48. Morimoto T, Gandhi TK, Seger AC, et al. Adverse drug events and medication errors: detection and classification methods. Qual Saf Health Care 2004; 13: 306-14 (Pubitemid 39070900)